Sign Up for Email Alerts
Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
  • Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
  • Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
  • KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
  • VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Post placeholder image
September 17, 2019 in Biotech Industry News

After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patients

Kineta Inc 2 Like Post Comments Off on After a run of CTLA-4 combo failures, scientists spotlight a way to make it work — in select patients
Read More
Post placeholder image
August 21, 2019 in Biotech Industry News

Kineta Acquires Translation Fund Award $1.8 Million from Welcome Trusts

Kineta Inc 2 Like Post Comments Off on Kineta Acquires Translation Fund Award $1.8 Million from Welcome Trusts
Read More
Post placeholder image
June 24, 2019 in Biotech Industry News

Local drug makers race to develop non-opioid pain medication

Kineta Inc 2 Like Post Comments Off on Local drug makers race to develop non-opioid pain medication
Read More
Post placeholder image
June 24, 2019 in Biotech Industry News

Kineta in the News with Molly Shen on KOMO News

Kineta Inc 2 Like Post Comments Off on Kineta in the News with Molly Shen on KOMO News
Read More
Post placeholder image
June 21, 2019 in Biotech Industry News

Despite Potential to Thrive, Seattle Struggles to Get Biotech Talent

Kineta Inc 2 Like Post Comments Off on Despite Potential to Thrive, Seattle Struggles to Get Biotech Talent
Read More
Post placeholder image
April 16, 2019 in Biotech Industry News

Vote for Your Favorite Health Innovation of the Year, a New Category at Geekwire Awards

Kineta Inc 2 Like Post Comments Off on Vote for Your Favorite Health Innovation of the Year, a New Category at Geekwire Awards
Read More
Post placeholder image
February 26, 2019 in Biotech Industry News

Innovators: Shawn Iadonato is preparing Kineta to go public this year

Kineta Inc 2 Like Post Comments Off on Innovators: Shawn Iadonato is preparing Kineta to go public this year
Read More
Post placeholder image
February 26, 2019 in Biotech Industry News

Curt Blake, Amy Morgan and Gene Farrell among PSBJ Innovators of the Year for 2019

Kineta Inc 2 Like Post Comments Off on Curt Blake, Amy Morgan and Gene Farrell among PSBJ Innovators of the Year for 2019
Read More
Post placeholder image
September 19, 2018 in Biotech Industry News

Venoms to the Rescue

Kineta Inc 2 Like Post Comments Off on Venoms to the Rescue
Read More
Post placeholder image
September 11, 2018 in Biotech Industry News

Immuno-oncology “Set to Become the Fifth Pillar of Cancer Treatment”

Kineta Inc 2 Like Post Comments Off on Immuno-oncology “Set to Become the Fifth Pillar of Cancer Treatment”
Read More
Prev1234…6Next

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • About Us
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2024 Kineta Inc. Privacy Policy Terms of Use

English
English
Korean